Welcome to our dedicated page for Mei Pharma SEC filings (Ticker: MEIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MEIP SEC filings page on Stock Titan aggregates U.S. Securities and Exchange Commission documents for MEI Pharma, Inc., including key 8-K current reports that explain its corporate evolution and strategic decisions. These filings provide primary-source detail on both the company’s historical role as a clinical-stage oncology business and its later transition toward a Litecoin-focused digital asset treasury strategy under the Lite Strategy, Inc. name.
Among the most significant filings is an 8-K dated September 10, 2025, in which the company reports an amendment to its certificate of incorporation changing its name to Lite Strategy, Inc. and notes that its common stock will cease trading under the MEIP ticker and begin trading under LITS on the NASDAQ Capital Market. Other 8-Ks describe the private placement used to fund the Litecoin treasury initiative, the subsequent acquisition of Litecoin tokens, and governance developments such as board changes and the appointment of GSR as asset manager for the company’s digital asset treasury.
Additional filings outline material agreements and financial obligations tied to the digital asset strategy, including a master loan agreement with BitGo Prime, LLC that establishes a framework for borrowing digital assets or cash secured by collateral. Earlier filings and related disclosures also reflect the company’s strategic alternatives process, workforce reductions, and changes in its clinical development activities.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the core points of each document, helping users quickly understand amendments to corporate structure, financing terms, treasury arrangements, and other material events. Investors can use this page to locate historical MEIP filings and to trace how the company’s regulatory record supports its rebranding and ticker change to LITS, while also accessing real-time updates as new Lite Strategy, Inc. filings are released.
Amendment No. 9 to Schedule 13D – MEIP (filed 24-Jul-25)
The Cable Car/Anson activist coalition discloses that MEI Pharma’s 17-Jul-25 private placement diluted its combined stake below the 5 % reporting threshold. The group now owns 1,093,188 shares, or 3.7 % of the 29,879,755 shares outstanding, and therefore ceases to act as a Section 13(d) group. Individual holdings: Funicular Funds/Cable Car/J. Ma-Weaver 35,300 sh (0.1 %); Anson Investments Master 841,674 sh (2.8 %); Anson East Master 214,304 sh (0.7 %); Anson Opportunities Master 37,210 sh (0.1 %).
Because the “Minimum Ownership Amount” in the 2023 Cooperation Agreement was no longer satisfied, Anson-appointed director Taheer Datoo resigned effective 22-Jul-25. On the same date all parties executed mutual terminations of both the Cooperation Agreement and the Group Agreement. Each fund acquired its position for cash (≈ US $12.9 m aggregate) without margin financing and now disclaims beneficial ownership of shares it does not directly hold.
Implication: activist governance pressure and mandatory 13D amendments end, reducing the likelihood of further board or strategic agitation from these investors.